Today: 16 July 2026
Nebius Group (NASDAQ:NBIS) slides as $1B Reflection AI deal fails to reassure on cash conversion

Nebius (NASDAQ:NBIS) shares fall as AI plan shifts capex burden

NEW YORK, July 16, 2026, 1:07 p.m. EDT

  • Nebius dropped 12.6% to $174.31 in early U.S. trading.
  • CoreWeave fell 5.2%. Nvidia slipped 2.5%.
  • Nebius kept its capital spending guidance at $20 billion to $25 billion under its partner-funded model.

Nebius dropped 12.6% to $174.31 as of 1:07 p.m. EDT, wiping out a 2.8% rise from Wednesday. U.S. markets stayed open.

The slip is key since the new model goes after Nebius’s biggest value issue. AI buildouts need a lot of cash. Still, there was no mention of the new 2026 capex forecast in the release.

Nebius reported around $2.5 billion in spending for the first quarter. That’s just 10% to 12.5% of what the company has outlined for the whole year. The rest of the projected spend means Nebius could be facing $5.8 billion to $7.5 billion in quarterly bills for the rest of the year.

Capital measureDisclosed figureInvestor calculation
Earlier 2026 capex guide$16–$20 billion in March $18 billion at midpoint
Latest 2026 capex guide$20–$25 billion in May $22.5 billion midpoint, a 25% increase
First-quarter capexAbout $2.5 billion 10%–12.5% of the latest forecast
Implied second-to-fourth-quarter averageNo company forecast here$5.8–$7.5 billion per quarter
July partner modelNo new capex number Short-term capex impact not quantified

The numbers are not from the company. They use the current guidance and don’t reflect any update. This rate comes out to 2.3 to 3.0 times the spending from the first quarter.

Under the model, partners pay for, own and run the data centers and hardware. Nebius handles the architecture, software, cloud, and sales, and still takes on service levels.

Nebius described the model as high-margin. Possible terms are revenue shares, licenses, commissions, and committed capacity. The company gave no figures on partner names, capacity, or financial targets.

CEO Arkady Volozh pushed the partner-focused model, saying Nebius offers “a much wider customer base with much better margins” versus bare-metal agreements. Nebius

Reflection is set to buy over $1 billion in Nebius capacity, the company said Tuesday. The deal covers Nvidia’s newest chips. “The need for open models is clear,” Reflection technology chief Ioannis Antonoglou said. Reuters Demand concerns have eased.

Markets were under pressure. The Nasdaq dropped roughly 0.9%, and chips took a bigger hit, with the semiconductor index down 3.5% at one point. “The chip rally is cooling off,” said Shiraz Ahmed, CEO of Sartorial Wealth. He said AI capital spending is still running high. Reuters

Still, Nebius dropped harder than either CoreWeave or Nvidia. CoreWeave slipped 5.2%, Nvidia gave up 2.5%. The gap shows the market is thinking about optionality beyond a 2026 funding reset.

Nebius brought in $4.34 billion in convertible debt in March. At the time, management said prepayments would fund 60% of growth and the balance would come from equity and debt. By May, the capex midpoint was up 25%.

Risks: Partners might not fund sites or keep up with Nebius’s service requirements. Returns could fall if prices drop, customers leave or more capital is needed.

To re-rate, investors want to see named partners, actual capacity in use, and clear unit economics. This release shifts how they finance, but leaves the 2026 bill the same for now.

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets. Follow Mateusz Kaczmarek on Google News.

Stock Market Today

  • Novo Nordisk Shares Gain After EU Approves Oral Wegovy for Obesity
    July 16, 2026, 2:41 PM EDT. Novo Nordisk (NVO) shares rose after the European Commission approved an oral daily version of Wegovy (semaglutide 25 mg) for adults with obesity and related conditions. The approval is based on phase III OASIS trial results and introduces the first GLP-1 receptor agonist tablet for weight management in the EU. Patients taking the drug lost an average of 17% body weight compared to 3% with placebo, with a safety profile similar to injectable versions. The decision boosts Novo Nordisk's position against Eli Lilly (LLY), which also offers oral and injectable obesity drugs. Novo Nordisk still faces U.S. pricing and prescription challenges in the obesity market.
Humana (NYSE: HUM) trades ahead of July 29 results
Previous Story

Humana (NYSE: HUM) trades ahead of July 29 results

SpaceX (NASDAQ:SPCX) Stock’s $230 Target Implies a $1.24 Trillion Gain Before Starship Test
Next Story

SpaceX (NASDAQ: SPCX) drops under IPO price with larger float possible on lockup changes

Go toTop